Search

Your search keyword '"Hillengass J"' showing total 415 results
Start Over Author "Hillengass J"
415 results on '"Hillengass J"'

2. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., and Palumbo, A.

Published
2017
Full Text
View/download PDF

3. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Author

Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, and Durie, B G M

Published
2017
Full Text
View/download PDF

7. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

Author

Zamagni, E, Nanni, C, Gay, F, Pezzi, A, Patriarca, F, Bellò, M, Rambaldi, I, Tacchetti, P, Hillengass, J, Gamberi, B, Pantani, L, Magarotto, V, Versari, A, Offidani, M, Zannetti, B, Carobolante, F, Balma, M, Musto, P, Rensi, M, Mancuso, K, Dimitrakopoulou-Strauss, A, Chauviè, S, Rocchi, S, Fard, N, Marzocchi, G, Storto, G, Ghedini, P, Palumbo, A, Fanti, S, and Cavo, M

Published
2016
Full Text
View/download PDF

8. P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA

Author

Hillengass, J., primary, Cohen, A. D., additional, Delforge, M., additional, Einsele, H., additional, Goldschmidt, H., additional, Weisel, K., additional, Raab, M.-S., additional, Scheid, C., additional, Schecter, J. M., additional, De Braganca, K. C., additional, Varsos, H., additional, Yeh, T.-M., additional, Mistry, P., additional, Roccia, T., additional, Corsale, C., additional, Akram, M., additional, Pacaud, L., additional, Nesheiwat, T., additional, Agha, M., additional, and Cohen, Y. C., additional

Published
2022
Full Text
View/download PDF

10. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Author

Mai, E K, Bertsch, U, Dürig, J, Kunz, C, Haenel, M, Blau, I W, Munder, M, Jauch, A, Schurich, B, Hielscher, T, Merz, M, Huegle-Doerr, B, Seckinger, A, Hose, D, Hillengass, J, Raab, M S, Neben, K, Lindemann, H-W, Zeis, M, Gerecke, C, Schmidt-Wolf, I G H, Weisel, K, Scheid, C, Salwender, H, and Goldschmidt, H

Published
2015
Full Text
View/download PDF

12. B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS

Author

van de Donk, NWCJ, primary, Delforge, M, additional, Agha, M, additional, Cohen, AD, additional, Cohen, YC, additional, Hillengass, J, additional, Anguille, S, additional, Kerre, T, additional, Roeloffzen, W, additional, Schecter, JM, additional, De Braganca, KC, additional, Varsos, H, additional, Wang, L, additional, Vogel, M, additional, Zudaire, E, additional, Corsale, C, additional, Akram, M, additional, Geng, D, additional, Nesheiwat, T, additional, Pacaud, L, additional, Sonneveld, P, additional, and Zweegman, S, additional

Published
2022
Full Text
View/download PDF

13. P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY

Author

Einsele, H, primary, Cohen, AD, additional, Delforge, M, additional, Hillengass, J, additional, Goldschmidt, H, additional, Weisel, K, additional, Raab, M-S, additional, Scheid, C, additional, Schecter, JM, additional, De Braganca, KC, additional, Varsos, H, additional, Yeh, T-M, additional, Wang, L, additional, Vogel, M, additional, Corsale, C, additional, Akram, M, additional, Pacaud, L, additional, Nesheiwat, T, additional, Agha, M, additional, and Cohen, YC, additional

Published
2022
Full Text
View/download PDF

17. EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY

Author

Agha, ME, primary, Cohen, AD, additional, Madduri, D, additional, Cohen, YC, additional, Delforge, M, additional, Hillengass, J, additional, Goldschmidt, H, additional, Weisel, K, additional, Raab, M, additional, Scheid, C, additional, Schecter, JM, additional, Braganca, KC, additional, Varsos, H, additional, Wang, L, additional, Vogel, M, additional, Carrasco-Alfonso, MJ, additional, Akram, M, additional, Wu, X, additional, Nesheiwat, T, additional, and Einsele, H, additional

Published
2021
Full Text
View/download PDF

19. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

Author

Terpos, E. Zamagni, E. Lentzsch, S. Drake, M.T. García-Sanz, R. Abildgaard, N. Ntanasis-Stathopoulos, I. Schjesvold, F. de la Rubia, J. Kyriakou, C. Hillengass, J. Zweegman, S. Cavo, M. Moreau, P. San-Miguel, J. Dimopoulos, M.A. Munshi, N. Durie, B.G.M. Raje, N. Bone Working Group of the International Myeloma Working Group

Abstract

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating physician can consider decreasing the frequency of or discontinuing zoledronic acid treatment. Denosumab can also be considered for the treatment of multiple myeloma-related bone disease, particularly in patients with renal impairment. Denosumab might prolong progression-free survival in patients with newly diagnosed multiple myeloma who have multiple myeloma-related bone disease and who are eligible for autologous stem-cell transplantation. Denosumab discontinuation is challenging due to the rebound effect. The Bone Working Group of the International Myeloma Working Group also found cement augmentation to be effective for painful vertebral compression fractures. Radiotherapy is recommended for uncontrolled pain, impeding or symptomatic spinal cord compression, or pathological fractures. Surgery should be used for the prevention and restoration of long-bone pathological fractures, vertebral column instability, and spinal cord compression with bone fragments within the spinal route. © 2021 Elsevier Ltd

Published
2021

21. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

Author

Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N, and Bone Working Group of the International Myeloma Working Group

Abstract

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating physician can consider decreasing the frequency of or discontinuing zoledronic acid treatment. Denosumab can also be considered for the treatment of multiple myeloma-related bone disease, particularly in patients with renal impairment. Denosumab might prolong progression-free survival in patients with newly diagnosed multiple myeloma who have multiple myeloma-related bone disease and who are eligible for autologous stem-cell transplantation. Denosumab discontinuation is challenging due to the rebound effect. The Bone Working Group of the International Myeloma Working Group also found cement augmentation to be effective for painful vertebral compression fractures. Radiotherapy is recommended for uncontrolled pain, impeding or symptomatic spinal cord compression, or pathological fractures. Surgery should be used for the prevention and restoration of long-bone pathological fractures, vertebral column instability, and spinal cord compression with bone fragments within the spinal route.

Published
2021

27. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma

Author

McClanahan, F., Hielscher, T., Rieger, M., Hensel, M., Bentz, M., Schmidt-Wolf, I., Käbisch, A., Salwender, H., Dürk, H., Staiger, H., Mandel, T., Neben, K., Hillengass, J., Leo, E., Krämer, A., Ho, A. D., and Witzens-Harig, M.

Published
2012
Full Text
View/download PDF

29. Smoldering Myelom: Dynamik der am schnellsten wachsenden fokalen Läsion korreliert mit Progressionsrisiko, Auftreten neuer fokaler Läsionen und Auftreten zugehöriger osteolytischer Läsionen in der CT

Author

Wennmann, M, additional, Kintzelé, L, additional, Hielscher, T, additional, Langs, G, additional, Merz, M, additional, Piraud, M, additional, Weinhold, N, additional, Hillengass, J, additional, Menze, B, additional, and Weber, M, additional

Published
2020
Full Text
View/download PDF

32. Corrigendum: Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P, Anderson, K. C, Attal, M, Richardson, P. G, Badros, A, Hou, J, Comenzo, R, Du, J, Durie, B. G. M, San Miguel, J, Einsele, H, Chen, W. M, Garderet, L, Pietrantuono, G, Hillengass, J, Kyle, R. A, Moreau, P, Lahuerta, J. J, Landgren, O, Ludwig, H, Larocca, A, Mahindra, A, Cavo, M, Mazumder, A, McCarthy, P. L, Nouel, A, Rajkumar, S. V, Reiman, A, Riva, E, Sezer, O, Terpos, E, Turesson, I, Usmani, S, Weiss, B. M, Palumbo, A., Musto, P, Anderson, K. C, Attal, M, Richardson, P. G, Badros, A, Hou, J, Comenzo, R, Du, J, Durie, B. G. M, San Miguel, J, Einsele, H, Chen, W. M, Garderet, L, Pietrantuono, G, Hillengass, J, Kyle, R. A, Moreau, P, Lahuerta, J. J, Landgren, O, Ludwig, H, Larocca, A, Mahindra, A, Cavo, M, Mazumder, A, Mccarthy, P. L, Nouel, A, Rajkumar, S. V, Reiman, A, E, Riva, Sezer, O, Terpos, E, Turesson, I, Usmani, S, Weiss, B. M, and Palumbo, A.

Subjects
NA
Abstract

Erratum to: Annals of Oncology, Volume 28, Issue 2, 1 February 2017, Pages 228–245, https://doi.org/10.1093/annonc/mdw606

Published
2018

45. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

Author

Kumar, S. Durie, B. Nahi, H. Vij, R. Dimopoulos, M.A. Kastritis, E. Terpos, E. Leleu, X. Beksac, M. Goldschmidt, H. Hillengass, J. Su, Z. Hutton, B. Cameron, C. Khan, I. Lam, A.

Abstract

Daratumumab is a CD38-directed monoclonal antibody approved for treating multiple myeloma (MM). Propensity score matching (PSM) based on individual patient data (IPD) was conducted to compare overall survival (OS) and progression-free survival (PFS) for daratumumab versus real-world standard of care (SOC). IPD for patients with relapsed and refractory (RR) MM treated with daratumumab monotherapy were from the GEN501 and SIRIUS studies; IPD for patients treated with SOC were from an International Myeloma Working Group (IMWG) chart review of patients with RRMM. Prior to PSM, patients treated with daratumumab had significantly longer OS (median 20.1 vs. 10.1 months, hazard ratio [HR] = 0.51 [0.39–0.67]) and PFS (median 4.0 vs. 2.8 months, HR = 0.73 [0.58–0.92]) than patients treated with SOC therapies. After PSM, daratumumab maintained a significantly prolonged OS (19.9 vs. 9.2 months, HR = 0.44 [0.31–0.63]) and PFS (3.9 vs. 1.6 months, HR = 0.56 [0.42–0.74]) compared with SOC. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Published
2019

46. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma response assessment and diagnosis system (MY-RADS)

Author

Messiou, C. Hillengass, J. Delorme, S. Lecouvet, F.E. Moulopoulos, L.A. Collins, D.J. Blackledge, M.D. Abildgaard, N. Østergaard, B. Schlemmer, H.-P. Landgren, O. Asmussen, J.T. Kaiser, M.F. Padhani, A.

Abstract

Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI in myeloma convened to discuss the technical performance standards, merits, and limitations of currently available imaging methods. Following guidance from the International Myeloma Working Group and the National Institute for Clinical Excellence in the United Kingdom, the Myeloma Response Assessment and Diagnosis System (or MY-RADS) imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma and allow response assessment. This consensus proposes a core clinical protocol for whole-body MRI and an extended protocol for advanced assessments. © 2019 Radiological Society of North America Inc.. All rights reserved.

Published
2019

47. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

Author

Went, M, Sud, A, Försti, A, Halvarsson, BM, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Jöckel, KH, Johnsson, E, Kristinsson, SY, Mellqvist, UH, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, ZS, Muir, K, Pashayan, N, Nickel, J, Nöthen, MM, Rafnar, T, Ross, FM, da Silva Filho, MI, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, AK, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, Houlston, RS, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Olama, AAA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, The PRACTICAL Consortium, and Claessens, Frank

Subjects
Male, Quality Control, Risk, Chromatin Immunoprecipitation, Genotype, European Continental Ancestry Group, Quantitative Trait Loci, Bayes Theorem, Polymorphism, Single Nucleotide, Chromatin, Gene Expression Regulation, Humans, Female, Genetic Predisposition to Disease, Multiple Myeloma, Promoter Regions, Genetic, Genome-Wide Association Study
Abstract

© 2018, The Author(s). Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight into the biological basis of MM. ispartof: Nature Communications vol:9 issue:1 ispartof: location:England status: published

Published
2018

48. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (vol 9, 3707, 2018)

Author

Went, M, Sud, A, Foersti, A, Halvarsson, B-M, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Joeckel, K-H, Johnsson, E, Kristinsson, SY, Mellqvist, U-H, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Al Olama, AA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Grindedal, EM, Neal, DE, Hamdy, FC, Donovan, JL, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, John, EM, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Khaw, K-T, Cannon-Albright, L, Pandha, H, Thibodeau, SN, Nickel, J, Noethen, MM, Rafnar, T, Ross, FM, Filho, MIDS, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, A-K, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, Houlston, RS, Went, M, Sud, A, Foersti, A, Halvarsson, B-M, Weinhold, N, Kimber, S, van Duin, M, Thorleifsson, G, Holroyd, A, Johnson, DC, Li, N, Orlando, G, Law, PJ, Ali, M, Chen, B, Mitchell, JS, Gudbjartsson, DF, Kuiper, R, Stephens, OW, Bertsch, U, Broderick, P, Campo, C, Bandapalli, OR, Einsele, H, Gregory, WA, Gullberg, U, Hillengass, J, Hoffmann, P, Jackson, GH, Joeckel, K-H, Johnsson, E, Kristinsson, SY, Mellqvist, U-H, Nahi, H, Easton, D, Pharoah, P, Dunning, A, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Al Olama, AA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Grindedal, EM, Neal, DE, Hamdy, FC, Donovan, JL, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, John, EM, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Khaw, K-T, Cannon-Albright, L, Pandha, H, Thibodeau, SN, Nickel, J, Noethen, MM, Rafnar, T, Ross, FM, Filho, MIDS, Thomsen, H, Turesson, I, Vangsted, A, Andersen, NF, Waage, A, Walker, BA, Wihlborg, A-K, Broyl, A, Davies, FE, Thorsteinsdottir, U, Langer, C, Hansson, M, Goldschmidt, H, Kaiser, M, Sonneveld, P, Stefansson, K, Morgan, GJ, Hemminki, K, Nilsson, B, and Houlston, RS

Abstract

The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected in both the PDF and HTML versions of the Article. Furthermore, in the original HTML version of this Article, the order of authors within the author list was incorrect. The PRACTICAL consortium was incorrectly listed after Richard S. Houlston and should have been listed after Nora Pashayan. This error has been corrected in the HTML version of the Article; the PDF version was correct at the time of publication.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results